Detail akcie Novartis AG Depository Receipt online

Business Summary: Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Novartis AG (ADR) revenues decreased 1% to $13.51B. Net income decreased 12% to $3.16B. Revenues reflect Cardiovascular, Renal and Metabolism - Entresto segment decrease of 42% to $1.31B, Oncology - Promacta/Revolade segment decrease of 66% to $184M, US segment decrease of 13% to $4.96B. Net income also reflects Research & Development - Balancing value increase of 17% to $2.7B (expense).